



April 11, 2012

NewLink Genetics to Present Data at the American Society of Clinical Oncology and Digestive Disease Week Annual Meetings

AMES, Iowa, April 11, 2012 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that data from its HyperAcute® Pancreas immunotherapy and its HyperAcute® Lung immunotherapy as well as its D-1MT IDO pathway inhibitor will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2012 Annual Meeting being held June 1-5, 2012 in Chicago, IL. In addition, data from its HyperAcute® Pancreas immunotherapy will be presented at the Digestive Disease Week (DDW) 2012 Annual meeting being held May 19-22, 2012 in San Diego, CA. A summary of the company's ASCO and DDW poster presentations is follows:

DDW plenary session:

HyperAcute® Pancreas

Session Title: Gastrointestinal (Noncolorectal) Cancer

Title: Addition of algenpantucel-L immunotherapy to standard adjuvant therapy for pancreatic cancer.

Session Type: Plenary Session

Session Title: SSAT Plenary Session VI

Session Date & Time: May 22, 2012 from 8:00 AM to 9:30 AM

ASCO Presentations:

HyperAcute® Pancreas

Session Title: Gastrointestinal (Noncolorectal) Cancer

Title: Addition of algenpantucel-L immunotherapy to standard of care (SOC) adjuvant therapy for pancreatic cancer.

Session: General Poster Session - Poster Board #: 41H

Date: Monday June 4, 2012

Time: 8:00 AM to 12:00 PM

Location: S Hall A2

HyperAcute® Lung

Session Title: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Title: Correlation of interferon-g (IFN) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC).

Session Type: General Poster Session - Poster Board #: 5D

Permanent Abstract ID: 2571

Date: Monday June 4, 2012

Time: 8:00 AM to 12:00 PM

Location: S Hall A2

D-1MT IDO Pathway inhibitor

Session Title: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Abstract Title: A phase I study of 1-methyl-d-tryptophan in patients with advanced malignancies

Session Type: Oral Abstract Session:

Permanent Abstract ID: 2501

Date: Monday June 4, 2012

Time: 3:00 PM to 6:00 PM

Location: E Arie Crown Theater

Presentation Time: 3:15 PM — 3:30 PM

Session Title: Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Abstract Title: A phase I study of 1-methyl-d-tryptophan in combination with docetaxel in metastatic solid tumors.

Session Type: General Poster Session: - Poster Board #: 11E

Permanent Abstract ID: TPS2620

Date: Monday June 4, 2012

Time: 8:00 AM to 12:00 PM

Location: S Hall A2

About NewLink Genetics Corporation

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve cancer treatment options for patients and physicians. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed with an objective to harness multiple components of the innate immune system to combat cancer, either as a monotherapy or in combination with current treatment regimens, without incremental toxicity. NewLink's lead product candidate, HyperAcute Pancreas cancer immunotherapy is being studied in a Phase 3 clinical trial in surgically resected pancreatic cancer patients (patient information is available at <http://www.pancreaticcancer-clinicaltrials.com>). This clinical trial is being performed under a Special Protocol Assessment with the U.S. Food and Drug Administration. NewLink and its collaborators have completed patient enrollment for a Phase 1/2 clinical trial evaluating its HyperAcute Lung cancer immunotherapy product candidate for non-small cell lung cancer and a Phase 2 clinical trial for its HyperAcute Melanoma cancer immunotherapy product candidate. NewLink also is developing d-1-methyltryptophan, or D-1MT, a small molecule, orally bioavailable product candidate from NewLink's proprietary indoleamine (2, 3) dioxygenase, or IDO, pathway inhibitor technology. Through NewLink's collaboration with the National Cancer Institute, NewLink is studying D-1MT in various chemotherapy and immunotherapy combinations in two Phase 1B/2 safety and efficacy clinical trials. For more information please visit www.linkp.com.

CONTACT: Gordon Link

Chief Financial Officer

515.598.2925

glink@linkp.com